Chronic Heart Failure Pipeline: Advancing Innovation with 25+ Pioneers Shaping the Future of Breakthrough Therapies

The chronic heart failure market is rapidly advancing and is fueled by groundbreaking research and innovative therapies from companies such as Tasly Pharmaceuticals, Berlin Cures, CardioCell, Help Therapeutics, and Eli Lilly and Company. These industry pioneers are transforming treatment strategies and redefining the future of Chronic Heart Failure care, bringing new hope to patients worldwide.

DelveInsight's "Chronic Heart Failure Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Chronic Heart Failure market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.

For emerging Chronic Heart Failure drugs, the Chronic Heart Failure pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Chronic Heart Failure Pipeline Report
• DelveInsight's Chronic Heart Failure Pipeline analysis depicts a robust space with 25+ active players working to develop 25+ pipeline drugs for Chronic Heart Failure treatment.
• The leading Chronic Heart Failure companies include Zensun (Shanghai) Sci & Tech, Cytokinetics, Mesoblast, Shanghai Hongyitang Biopharmaceutical Technology, Tasly Pharmaceuticals, Berlin Cures, CardioCell, Help Therapeutics, Eli Lilly and Company, Chong Kun Dang Pharmaceutical, Antlia Biosciences, Cardiol Therapeutics, Novartis, Boehringer Ingelheim, Bayer, BioCardia, Novo Nordisk, and others are evaluating their lead assets to improve the Chronic Heart Failure treatment landscape.
• Key Chronic Heart Failure pipeline therapies in various stages of development include Neucardin, Omecamtiv Mecarbil, Rexlemestrocel-L (Revascor), KERENDIA (finerenone), Tirzepatide (LY3298176), CardiAMP Cell Therapy, Ziltivekimab (NN6018), REVASCOR (rexlemestrocel-L), Levosimendan (TNX-103), Semaglutide, Balcinrenone (AZD9977) + dapagliflozin, Mitiperstat (AZD4831), Vicadrostat (BI 690517) + Empagliflozin, Cimlanod (CXL-1427/BMS-986231), Lenrispodun (ITI - 214), CRD-740, HU6, and others.
• In March 2025, Perfuze, a leading medical device company dedicated to advancing stroke treatment, announced that it has received FDA 510(k) clearance for its ZiplineTM Access Catheters. This regulatory milestone strengthens Perfuze's growing portfolio of innovative neurovascular devices, empowering physicians to treat acute Chronic Heart Failures with greater speed, ease, and precision.
• In January 2025, the FDA approved the abbreviated new drug application (ANDA) for Lupin's Sacubitril and Valsartan tablets, the generic equivalent of Novartis' Entresto, used to reduce cardiovascular risks in adults with chronic heart failure and decreased ejection fraction.
• In January 2025, FIRE1 announced it received Breakthrough Device Designation from the FDA and was accepted into the FDA's Total Product Lifecycle Advisory Program (TAP). FIRE1's Norm heart failure management system empowers patients with physician-directed self-management, reducing healthcare staff burden and helping patients stay healthier at home.

Request a sample and discover the recent breakthroughs happening in the Chronic Heart Failure pipeline landscape @ https://www.delveinsight.com/report-store/chronic-heart-failure-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Chronic Heart Failure Overview
Chronic heart failure (CHF) is a significant public health concern in industrialized nations, with an incidence of nearly 10 per 1,000 people over 65. Its prevalence increases with age, affecting less than 1% of individuals aged 45-55, 2-5% between 65-75, and about 10% of those 80 and older. CHF is a complex syndrome where the heart struggles to meet the body's demands, leading to reduced exercise tolerance and impaired quality of life. Forward heart failure results in low blood pressure and fatigue, while backward failure causes fluid retention, dyspnea, and complications like pulmonary congestion, pleural effusions, peripheral edema, and organ dysfunction. CHF can also lead to thromboembolic events, arrhythmias, pulmonary edema, cardiogenic shock, and death.
Diagnosis involves history, physical examination, and echocardiography, with additional tests like ECG, chest radiography, cardiac MRI, catheterization, and BNP levels aiding in assessment. CHF remains a growing burden despite advances in cardiovascular care. Preventive measures include regular physical activity (≥5 days/week), maintaining a healthy weight, avoiding smoking, and consuming a balanced diet with fruits, vegetables, moderate alcohol, and fish. Conversely, heavy alcohol use, drug abuse, and binge drinking increase the risk. Moderate coffee consumption (≤4 cups/day) has also been linked to reduced heart failure risk.

Find out more about Chronic Heart Failure medication @ https://www.delveinsight.com/report-store/chronic-heart-failure-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Chronic Heart Failure Treatment Analysis: Drug Profile
Neucardin: Zensun (Shanghai) Sci & Tech
Neucardin, a recombinant human neuregulin-1 developed by Zensun, is a genetically engineered biologic designed for the treatment of mild to moderate chronic heart failure (CHF). It specifically targets cardiac muscle cells, repairing their structure and enhancing function during contraction and relaxation. This improves overall cardiac performance, reverses pathological ventricular remodeling, and significantly lowers mortality and hospital readmission rates while enhancing patients' quality of life. In August 2019, Zensun USA, Inc. announced that Neucardin received Fast Track designation from the U.S. FDA for its potential in treating CHF. Additionally, China's National Medical Products Administration (NMPA) granted the drug "priority review" for its conditional approval application.

Omecamtiv Mecarbil: Cytokinetics
Omecamtiv mecarbil is an investigational, selective small-molecule cardiac myosin activator and the first in a new class of myotropes. It is designed to directly enhance heart contractility by binding to cardiac myosin and increasing the number of myosin heads interacting with actin during systole. This mechanism strengthens impaired contractility in heart failure with reduced ejection fraction (HFrEF). Preclinical studies have demonstrated that omecamtiv mecarbil boosts cardiac contractility without raising intracellular calcium levels or increasing myocardial oxygen consumption, distinguishing it from traditional inotropic therapies.

Key Chronic Heart Failure Therapies and Companies
• Neucardin: Zensun (Shanghai) Sci & Tech
• Omecamtiv Mecarbil: Cytokinetics
• Rexlemestrocel-L (Revascor): Mesoblast
• Omecamtiv Mecarbil: Cytokinetics
• KERENDIA (finerenone): Bayer
• Tirzepatide (LY3298176): Eli Lilly and Company
• CardiAMP Cell Therapy: BioCardia
• Ziltivekimab (NN6018): Novo Nordisk
• REVASCOR (rexlemestrocel-L): Mesoblast
• Levosimendan (TNX-103): Tenax Therapeutics
• Semaglutide: Novo Nordisk
• Balcinrenone (AZD9977) + dapagliflozin: AstraZeneca
• Mitiperstat (AZD4831): AstraZeneca
• Vicadrostat (BI 690517) + Empagliflozin: Boehringer Ingelheim
• Cimlanod (CXL-1427/BMS-986231): Bristol Myers Squibb
• Lenrispodun (ITI - 214): Intra-Cellular Therapies
• CRD-740: Cardurion Pharmaceuticals
• HU6: Rivus Pharmaceuticals

Learn more about the novel and emerging Chronic Heart Failure pipeline therapies @ https://www.delveinsight.com/report-store/chronic-heart-failure-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Chronic Heart Failure Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

By Molecule Type
• Oligonucleotide
• Peptide
• Small molecule

Scope of the Chronic Heart Failure Pipeline Report
• Coverage: Global
• Key Chronic Heart Failure Companies: Zensun (Shanghai) Sci & Tech, Cytokinetics, Mesoblast, Shanghai Hongyitang Biopharmaceutical Technology, Tasly Pharmaceuticals, Berlin Cures, CardioCell, Help Therapeutics, Eli Lilly and Company, Chong Kun Dang Pharmaceutical, Antlia Biosciences, Cardiol Therapeutics, Novartis, Boehringer Ingelheim, Bayer, BioCardia, Novo Nordisk, and others.
• Key Chronic Heart Failure Pipeline Therapies: Neucardin, Omecamtiv Mecarbil, Rexlemestrocel-L (Revascor), KERENDIA (finerenone), Tirzepatide (LY3298176), CardiAMP Cell Therapy, Ziltivekimab (NN6018), REVASCOR (rexlemestrocel-L), Levosimendan (TNX-103), Semaglutide, Balcinrenone (AZD9977) + dapagliflozin, Mitiperstat (AZD4831), Vicadrostat (BI 690517) + Empagliflozin, Cimlanod (CXL-1427/BMS-986231), Lenrispodun (ITI - 214), CRD-740, HU6, and others.

Dive deep into rich insights for drugs used for Chronic Heart Failure treatment; visit @ https://www.delveinsight.com/report-store/chronic-heart-failure-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Chronic Heart Failure Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Chronic Heart Failure Pipeline Therapeutics
6. Chronic Heart Failure Pipeline: Late-Stage Products (Phase III)
7. Chronic Heart Failure Pipeline: Late-Stage Products (Phase III)
8. Chronic Heart Failure Pipeline: Mid-Stage Products (Phase II)
9. Chronic Heart Failure Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.